Latest Breaking News On - Total symptom score - Page 7 : comparemela.com

MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew orleansUnited kingdomItaly generalKaitlyn nealyThomas biegiTim demuthJulia neugebauerDevelopment officerXencor incDrug administrationGerman lymphoma associationConstellation pharmaceuticals incExchange commissionAmerican society of hematologyMorphosys us inc

GSK: FDA Accepts New Drug Application For Momelotinib To Treat Myelofibrosis

LONDON (dpa-AFX) - British drug maker GSK plc (GSK, GSK.L) announced Wednesday that the US Food and Drug Administration accepted the New Drug Application or NDA for momelotinib for the treatment

United statesUnited kingdomCity ofAmerican society of clinical oncology annual meetingSierra oncology incEuropean hematology associationDrug administrationMore such health newsNew drug applicationPrescription drug user fee actTotal symptom scoreTransfusion independenceSplenic response rateClinical oncology annual meetingSierra oncology

GSK momelotinib receives US FDA acceptance for New Drug Application

GSK momelotinib receives US FDA acceptance for New Drug Application

United statesAmerican society of clinical oncology annual meetingSierra oncology incEuropean hematology associationDrug administrationNew drug applicationPrescription drug user fee actTotal symptom scoreTransfusion independenceSplenic response rateClinical oncology annual meetingMyelofibrosis symptom assessmentSierra oncology

US FDA accepts new drug application for GSKs momelotinib for the treatment of myelofibrosis

Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial that met all primary and key secondary efficacy endpoints.

United statesAmerican society of clinical oncology annual meetingSierra oncology incEuropean hematology associationDrug administrationNew drug applicationPrescription drug user fee actTotal symptom scoreTransfusion independenceSplenic response rateClinical oncology annual meetingMyelofibrosis symptom assessmentSierra oncologyHematol oncolMyelofibrosis related anemiaEmerging therapeutic

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia Presented at European Hematology Association Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study. | August 12, 2022

United statesSouth san franciscoWashington schoolLaurence wattsHugh young rienhoff jrJoseph hiattRafael santana davilaCompany nasdaqNational cancer instituteCanale communicationsEuropean hematology associationResearch development rd expensesAmerican society of hematologyGlobenewswire incImago biosciences incFred hutchinson cancer center hutch